Aerie Pharmaceuticals, Inc.
Clinical-stage pharmaceutical company Aerie Pharmaceuticals, Inc. recently announced dosing had commenced of the first patients enrolled in Mercury 2, the Company’s second Phase 3 registration trial of Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% — a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Roclatan is reportedly a fixed dose combination of Aerie product candidate Rhopressa™ (netarsudil ophthalmic solution) 0.02% and latanoprost, the most widely prescribed PGA (prostaglandin analogue). Aerie estimates about 690 patients will be enrolled in this three-arm, 90-day efficacy study that compares Roclatan for superiority to each of its two components, all dosed once daily in the evening. Patients will be evaluated with maximum baseline IOPs ranging from above 20 to below 36 mmHg.
The first Phase 3 registration trial for Roclatan, named Mercury 1, commenced in September 2015. Aerie also plans to commence in the first half of 2017 with a third Phase 3 trial for Roclatan named Mercury 3 for the sole purpose of facilitating regulatory approval and commercialization in Europe.
Click here to read the full press release.